Choosing how to staff and manage a clinical trial is one of the first structural decisions a sponsor makes once a program moves toward the clinic, and it is rarely a single yes/no choice. The real question is which of three operating models — keeping trial management in-house (or in a sponsor-CRO hybrid), engaging a full-service contract research organization (CRO), or building a Functional Service Provider (FSP) arrangement — fits a given program, portfolio, and internal capability at a given point in time. This guide sets out the decision framework: what each model actually is, the tradeoffs that drive the choice, and how the right answer changes with trial size, therapeutic complexity, portfolio stage, and how much internal clinical-operations capability a sponsor wants to own long-term.
The Three Outsourcing Models
These are not three tiers of company — they are three different ways a sponsor can source the same work, and the same CRO can often deliver any of the three depending on how the contract is structured. See the CRO dictionary entry for the underlying regulatory-delegation definition; this section covers the sourcing decision itself.
- In-house / hybrid management. The sponsor retains its own clinical operations, data management, and monitoring staff and runs the trial (or most of it) with internal teams, outsourcing only discrete, hard-to-staff pieces — central lab services, specific regional monitoring coverage, or a niche analytic capability — on a project basis. This model concentrates institutional knowledge and long-term process ownership inside the sponsor organization.
- Full-service CRO engagement. The sponsor delegates end-to-end trial execution — protocol operationalization, site identification and activation, monitoring, data management, safety reporting, and often biostatistics and regulatory submission support — to a single CRO under a master services agreement and study-specific work orders, as covered in the Pharmaceutical CRO Industry sector overview. The CRO supplies its own systems, SOPs, and project management layer; the sponsor’s role shifts toward oversight rather than execution.
- Functional Service Provider (FSP) engagement. The sponsor contracts a CRO (large or specialty) to supply staff for one or more specific functions — monitoring, data management, medical writing, pharmacovigilance case processing — who work as an extension of the sponsor’s own team, typically using the sponsor’s systems, SOPs, and processes, and often across the sponsor’s full portfolio rather than a single trial. The sponsor retains overall trial and vendor management; the CRO supplies capacity and, in many arrangements, dedicated staff rather than a packaged deliverable.
Many sponsors run a blended model in practice — full-service for some studies, FSP for a specific function across the whole portfolio, and a shrinking or growing in-house core — rather than treating the choice as portfolio-wide and permanent.
The Decision Framework: Four Tradeoffs
Four factors recur in how sponsors actually make this decision, and they frequently pull in different directions, which is why there is no single right answer independent of context.
- Cost structure. Full-service CRO engagements bundle project management, systems, and staffing into a contracted fee, which is predictable but carries a margin on every function delegated. FSP arrangements typically price closer to a staffing/rate-card model, which can be cheaper at scale for a sponsor with enough ongoing volume to keep FSP staff continuously utilized, but loses that advantage for a sponsor with sporadic, one-off trial volume. In-house capability has high fixed cost (headcount, systems, training) that only pays off if utilization is sustained across multiple programs.
- Control and process ownership. In-house management gives the sponsor direct, day-to-day control over how work is done and immediate visibility into problems as they emerge. Full-service CRO delegation trades that direct control for the CRO’s own processes and systems, with the sponsor exercising control through contractual oversight rather than direct management — a real distinction, since ICH E6(R2) and 21 CFR 312.52 require the sponsor to actively oversee delegated activities regardless of which model is used. FSP sits in between: the sponsor manages FSP staff more directly, on its own systems, even though those staff are formally employed by the CRO.
- Speed and time-to-start. A full-service CRO can typically mobilize a study team faster than a sponsor can hire and train an internal one from scratch, since the CRO already has trained staff and validated systems in place. FSP can also mobilize quickly for an established relationship but requires more sponsor-side onboarding (system access, SOP training) up front than a turnkey full-service engagement, since FSP staff work inside the sponsor’s own environment rather than the CRO’s.
- Internal capability-building. Full-service outsourcing builds the least durable internal capability — institutional knowledge about how the trial was actually run tends to sit with the CRO. FSP, because staff work inside the sponsor’s own systems and processes, tends to leave more transferable process knowledge with the sponsor even when the individual staff are CRO employees. In-house management builds the most capability but requires the sponsor to sustain investment in staff, training, and systems between programs, which is difficult for a sponsor without a steady trial pipeline.
Matching the Model to the Sponsor’s Situation
The framework above translates into a few recurring patterns, though every sponsor’s actual mix reflects its specific portfolio and risk tolerance rather than a fixed rule:
- Emerging biotech, first-in-class asset, no internal infrastructure. A full-service CRO is usually the practical starting point — the sponsor has no existing clinical operations team to extend, and speed to first-patient-in typically matters more than long-term capability-building at this stage. See Study Start-Up in Clinical Trials for what that mobilization actually involves.
- Large pharmaceutical sponsor with sustained, multi-program volume. An FSP or hybrid model becomes more attractive here, since consistent volume across programs is exactly what makes FSP’s staffing-based economics work, and the sponsor typically already has the internal systems and SOPs an FSP arrangement extends. Many large sponsors run a mixed portfolio — FSP for core, recurring functions like monitoring or data management, full-service for specialty trials outside their standing therapeutic focus.
- Mid-size sponsor scaling from single-asset to multi-program. This is where the in-house-vs-outsource decision is most actively revisited, since a sponsor that outsourced fully for its first trial often reassesses whether building internal capability now pays off across a growing pipeline — or whether it is more efficient to keep scaling through CRO relationships instead of building headcount.
- Post-approval, Phase IV, or registry-type studies. These often run on smaller, more predictable budgets and benefit from a specialty CRO or targeted FSP engagement for a single function (e.g., data management or safety reporting) rather than a full-service engagement scoped for interventional-trial complexity. See the related vendor landscape in Clinical Trial Recruitment Companies for how sourcing decisions extend to recruitment specifically.
Governance Obligations Are the Same Regardless of Model
One point the decision framework does not change: under ICH E6(R2), delegating work to a CRO — whether full-service or FSP — does not delegate the sponsor’s regulatory responsibility for trial oversight. The sponsor must maintain active oversight of delegated activities, document exactly which duties transferred (typically in the master services agreement and study-specific work orders), and monitor CRO or FSP performance against agreed quality metrics regardless of which sourcing model is chosen. What changes across models is how that oversight is operationalized — contract and vendor-management oversight for full-service, closer day-to-day management for FSP and in-house teams — not whether it is required. The monitoring plan and study team structure a sponsor builds should reflect which oversight model its outsourcing choice requires.
How This Differs from the CRO Industry Overview
The Pharmaceutical CRO Industry: A Sector Overview guide covers the CRO market itself — how the industry is segmented, what service lines CROs typically offer, and how a sponsor runs the CRO selection, contracting, and governance process once it has decided to outsource. This guide answers the decision that logically comes first: whether, and to what degree, a sponsor should outsource at all, and which of the three sourcing models — in-house/hybrid, full-service, or FSP — fits its situation. Read this guide to decide the sourcing model, then the sector overview to understand the market you are sourcing from.
Frequently Asked Questions
What is a Functional Service Provider (FSP) model, and how does it differ from full-service outsourcing?
An FSP arrangement supplies staff for a specific function — monitoring, data management, medical writing, or pharmacovigilance, for example — who work inside the sponsor’s own systems and processes, typically across the sponsor’s full portfolio. Full-service outsourcing delegates end-to-end trial execution to the CRO’s own systems and project-management structure for a defined study. FSP staff are CRO employees but operate as an extension of the sponsor’s team; full-service CRO staff operate under the CRO’s own operating model.
When should a sponsor build clinical operations capability in-house instead of outsourcing?
In-house capability tends to make sense when a sponsor has (or expects) sustained trial volume across multiple programs, since the fixed cost of staff, training, and systems only pays off with consistent utilization. A sponsor running a single trial, or trials that are infrequent and unpredictable in timing, generally cannot justify that fixed investment and is better served by full-service or FSP outsourcing.
Does using an FSP model change the sponsor’s regulatory oversight obligations?
No. ICH E6(R2) and, for FDA-regulated trials, 21 CFR 312.52 require active sponsor oversight of any delegated trial activity regardless of the sourcing model. What changes is how that oversight is exercised in practice — FSP staff typically operate under closer, more direct sponsor management than a full-service CRO team does, but the underlying oversight obligation is unchanged.
Can a sponsor use different outsourcing models for different trials or functions in the same portfolio?
Yes, and many sponsors do — for example, running a full-service CRO engagement for a complex or unfamiliar therapeutic area while using FSP staffing for a function like monitoring across the rest of the portfolio, or keeping a core in-house team supplemented by both models as volume fluctuates. The decision is typically made at the program or function level, not as a single portfolio-wide policy.
What are the main cost differences between full-service CRO and FSP engagements?
Full-service engagements bundle staffing, systems, and project management into a contracted fee that includes the CRO’s margin on the full scope of delegated work. FSP engagements are typically priced closer to a staffing or rate-card model, which can be more cost-efficient for a sponsor with enough sustained volume to keep FSP staff continuously utilized, but offers less of that advantage for occasional or one-off trial needs.
